Board of Directors

Mr. Truex currently serves as the Executive Chairman of the Board. Previously, he served as Director and Chief Executive Officer since the inception of Anthera in 2004 through 2016. He was responsible for negotiating Anthera’s product licenses for both blisibimod, our anti-BAFF peptibody program from Amgen, and recently, Sollpura™(liprotamase), a novel enzyme replacement product, from Eli Lilly and Company. During his career Mr. Truex has been involved with over $500 million in private, public and debt financings and over $1 billion in various strategic in-licensing, out-licensing and merger/acquisition transactions including initial public offerings for Trius Therapeutics (Board Member, 2010), Anthera (CEO, 2010), Peninsula Pharmaceuticals (2004), and Versicor (Vice President, 2000).

Prior to founding Anthera Pharmaceuticals, Mr. Truex served as a Founder, Director, President and CEO of Peninsula Pharmaceuticals. During that time Mr. Truex negotiated both of Peninsula’s product agreements with Shionogi & Co., Ltd. (Doribax®, doripenem) and Takeda Chemical Industries (Teflaro®, ceftaroline). Peninsula was acquired by Johnson and Johnson for $245 million in an all cash transaction. The remaining entity, Cerexa was subsequently acquired in $480 million in cash.

Prior to Peninsula, Mr. Truex was Vice President of Commercial Development for Versicor Incorporated (acquired by Pfizer) where he directed early commercial efforts for their infectious disease portfolio and participated in the company’s successful $55 million initial public offering.

Prior to joining Versicor, Mr. Truex worked at Eli Lilly and Company where he served in various marketing and sales roles during the launch of three different products for the primary care physician market (Actos®’ Evista®’ and Humalog 75/25®). His business development experience includes the Lilly ICOS LLC joint venture for the development of Cialis® and two major product divestitures (anidulafungin, Eraxis® and loracarbef, Lorabid®), and numerous research collaborations.

Mr. Truex obtained his Masters of Business Administration in Marketing and Finance from Indiana University and a Bachelor of Arts degree in Economics from the University of Waterloo. Mr. Truex sits on the Indiana University West Coast Advisory Board for the Johnson Center of Entrepreneurship and Innovation, is a member of the Board of Directors of Milestone Pharmaceuticals Limited (Chairman) and involved as an advisor to a number of early stage ventures in multiple industries. His past board appointments include Peninsula Pharmaceuticals, Trius Therapeutics, and Protagonist Therapeutics.

Craig joins Anthera with over 20 years of experience in the pharmaceutical and healthcare industries. He has a proven track record in product development, global brand management, product positioning, access and reimbursement, including the strategic marketing of a number of industry-leading drugs.

Prior to Anthera, Craig was the Chief Operating Officer for Tetraphase Pharmaceuticals where he oversaw the development and implementation of the marketing, access & reimbursement and sales strategy as well as the business development and the commercial manufacturing for the company.

Prior to Tetraphase, he served as Chief Commercial Officer for Trius Therapeutics through the acquisition of Trius by Cubist Pharmaceuticals, Inc. in September 2013. Craig led the planning of the commercial strategy, was actively involved in negotiating a regional partnership with Bayer as well as the actively involved in the acquisition of the company by Cubist. During his tenure he participated in three company financing raising $115 MM.

Prior to Trius, Mr. Thompson served in various global and U.S. commercial roles at Pfizer Inc. from 2003 to December 2010 ultimately serving as Vice President of Marketing for Pfizer’s Specialty Care Business Unit, where he was directly responsible for the U.S. commercial strategy for a portfolio of products with more than $1.5 billion in annual U.S. sales. From 1992 to 2003, Mr. Thompson served in positions of increasing responsibility at Merck & Co., Inc., where he most notably worked on commercial planning and marketing activities for the company’s major cardiovascular brands.

Mr. Thompson holds a Bachelor’s degree in Commerce from McMaster University and an M.B.A. from the University of Notre Dame.

Dr. Henney has served as the Chairman of our board of directors since August 2008 and has been a member of our board of directors since April 2005. Dr. Henney served as Chairman and Chief Executive Officer of Dendreon Corporation, a biotechnology company he co-founded, from 1997 until his retirement in July 2004.

Dr. Henney was previously a founder of Immunex Corp. and Icos Corp.

Dr. Henney holds a B.Sc with honors in medical biochemistry, a Ph.D. in experimental pathology and a D.Sc. for contributions to the field of immunology, all from the University of Birmingham, England.

Dr. Henney is currently the Chairman and a director of Oncothyreon, Inc., is vice-chairman and a director of Cyclacel Pharmaceuticals, Inc., and is a director of AVI BioPharma Inc.

Brian R. Mueller is a senior financial executive with over 20 years of finance experience, most of which is in the biopharmaceutical industry.  Mr. Mueller serves as Group Vice President, Corporate Controller and Chief Accounting Officer for BioMarin Pharmaceutical Inc., where he has been in leadership roles since 2002. BioMarin is a global biopharmaceutical company with five approved products and approximately 1,500 employees.

Prior to BioMarin, Mr. Mueller spent a combination of seven years with Arthur Andersen LLP and KPMG LLP, in their assurance and business advisory services practices where he served mostly large multi-national clients through audit and transaction advisory services.

Mr. Mueller holds a Bachelor of Science in Accountancy from Northern Illinois University.

Mr. Thompson has served as a member of our board of directors since November 2005. Mr. Thompson served as Vice President of Corporate Strategy Business Development for Eli Lilly and Company from January 2001 until his retirement in July 2005. Thereafter, he was a partner at VantagePoint Venture Partners from 2006 through 2008.

Mr. Thompson holds a B.S. and an M.B.A. from Michigan State University.

Mr. Furse has over 25 years of healthcare commercial leadership experience with extensive experience in the areas of sales and marketing, commercial product launch and partnerships. He is currently President and Chief Commercial Officer of Cardiorentis AG, a company that is developing novel medicines for Acute Heart Failure.

Previously he was Chief Customer Officer & Executive Vice President at The Medicines Company.  Prior to the Medicines Company, he worked in the cardiovascular divisions of Schering-Plough and Bristol-Myers Squibb.

Mr. Furse holds a Bachelor of Science from Kennesaw State University and an M.B.A. from Mercer University.

Dr. Sager is a Fellow of the American College of Cardiology, a Fellow of the American Heart Association and a Fellow of the Heart Rhythm Society. Dr. Sager has served as a Consulting Professor of Medicine at the Stanford University School of Medicine since 2013, a Full Voting Member of the United States Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee since 2011 (and the Committee Chair since 2015), a private pharmaceutical, device and diagnostics consultant since 2010 and Member of the Executive Committee of the Cardiac Safety Research Consortium since 2006, serving as Chair of the Scientific Programs Committee and Scientific Oversight Committee at various times. From 2009 through 2010 Dr. Sager was Vice President, Clinical Research and Head, CV/Metabolic Development for Gilead Sciences, a biotechnology company.

Dr. Sager holds an M.D. from Yale University School of Medicine and B.S. degrees in chemistry and biology from the Massachusetts Institute of Technology.